REGENXBIO Inc.
RGNX · Nasdaq · United States
Share price · RGNX
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when RGNX's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 11 Nov 2026+10.1%
Nothing announced by RGNX that day or the session before.
- 24 Aug 2026-24.9%
- 22 Jun 2026+16.3%
- 21 May 2026+13.1%
Nothing announced by RGNX that day or the session before.
- 14 May 2026-37.8%
- 6 May 2026+10.8%
- 9 Mar 2026+20.0%
Nothing announced by RGNX that day or the session before.
- 10 Feb 2026-14.2%
- 28 Jan 2026-17.9%
- 23 Jan 2026-13.7%
Nothing announced by RGNX that day or the session before.
Share of unusual movement by asset
For each asset, the share of RGNX's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(3 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 3 | Iduronate-2-sulfatase (IDS)Gene therapy / editing | Mucopolysaccharidosis Type II | |
| Phase 3 | VEGF-AGene therapy / editing | Age-Related Macular Degeneration | |
| Phase 2/3 | Dystrophin (microdystrophin transgene)Gene therapy / editing | Duchenne Muscular Dystrophy |
Upcoming events
(5 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (1)
December 2026 (1)
What to watch
2028 (3)
2033 (1)
March 2033 (1)
What to watch
Regulatory and conference events
(6)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (16)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | $9.2M | $61M | $96M+ $155M short-term inv. | $41M$39M operating cash flow | report ↗ |
View 15 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | $108M | $56M | $36M+ $69M short-term inv. | —-$62M operating cash flow | report ↗ |
| 2026-Q1 | $6.4M | $57M | $15M+ $135M short-term inv. | $90M-$76M operating cash flow | report ↗ |
| 2025-Q3 | $30M | $56M | $59M+ $215M short-term inv. | $62M-$56M operating cash flow | report ↗ |
| 2025-Q2 | $21M | $60M | $80M+ $244M short-term inv. | $71M-$49M operating cash flow | report ↗ |
| 2025-Q1 | $89M | $53M | $130M+ $138M short-term inv. | —$34M operating cash flow | report ↗ |
| 2024-Q3 | $24M | $54M | $57M+ $199M short-term inv. | $60M-$41M operating cash flow | report ↗ |
| 2024-Q2 | $22M | $49M | $58M+ $233M short-term inv. | $53M-$46M operating cash flow | report ↗ |
| 2024-Q1 | $16M | $55M | $113M+ $226M short-term inv. | $63M-$55M operating cash flow | report ↗ |
| 2023-Q3 | $29M | $58M | $53M+ $249M short-term inv. | $62M-$49M operating cash flow | report ↗ |
| 2023-Q2 | $20M | $60M | $69M+ $251M short-term inv. | $72M-$47M operating cash flow | report ↗ |
| 2023-Q1 | $19M | $59M | $70M+ $262M short-term inv. | $67M-$81M operating cash flow | report ↗ |
| 2022-Q3 | $27M | $63M | $119M+ $264M short-term inv. | $75M-$50M operating cash flow | report ↗ |
| 2022-Q2 | $33M | $61M | $121M+ $282M short-term inv. | $68M-$62M operating cash flow | report ↗ |
| 2022-Q1 | $22M | $56M | $192M+ $202M short-term inv. | $77M-$56M operating cash flow | report ↗ |
| 2021-Q3 | $31M | $48M | $228M+ $111M short-term inv. | $58M-$36M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $170M | $228M | $34M+ $196M short-term inv. | $48M-$124M operating cash flow | report ↗ |
For full-year 2025, REGENXBIO reported revenue of $170.44M, up 104.5% YoY, with R&D spend of $228.3M, up 9.5% YoY. Cash, cash equivalents, and marketable securities were $240.9M at year-end, and the company posted a net loss of $193.9M, or $3.76 per share basic and diluted.
Management expects the year-end cash position to fund operations into early 2027. Pipeline catalysts include topline pivotal data for RGX-202 in Duchenne in early Q2 2026, topline pivotal data for sura-vec subretinal wet AMD in Q4 2026, and first patient dosing in the pivotal diabetic retinopathy study expected Q2 2026, tied to a $100M milestone from AbbVie. The FDA placed clinical holds on RGX-111 and RGX-121 and issued a complete response letter for the RGX-121 BLA; the company plans to engage the FDA on a potential path forward.
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | $83M | $209M | $58M+ $177M short-term inv. | $57M-$173M operating cash flow | report ↗ |
| 2023-FY | $90M | $232M | $35M+ $241M short-term inv. | $66M-$218M operating cash flow | report ↗ |
| 2022-FY | $113M | $242M | $97M+ $268M short-term inv. | $70M-$207M operating cash flow | report ↗ |
| 2021-FY | $470M | $181M | $345M+ $112M short-term inv. | —$219M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 2 purchases ($949K), 5 sales ($940K). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-11-01 | Chan Mitchell · Chief Financial Officer | Award / grant | 24,305 | — | — | Form 4 |
| 2026-11-01 | PAKOLA STEVE · Chief Medical Officer | Award / grant | 34,722 | — | — | Form 4 |
| 2026-11-01 | Christmas Patrick J. · Chief Strategy & Legal Officer | Award / grant | 34,722 | — | — | Form 4 |
| 2026-11-01 | Malzahn Craig · Chief Technology Officer | Award / grant | 27,777 | — | — | Form 4 |
| 2026-09-01 | Chan Mitchell · Chief Financial Officer | Tax withholding | 4,902 | $9.32 | $46K | Form 4 |
| 2026-09-01 | Malzahn Craig · Chief Technology Officer | Tax withholding | 234 | $9.32 | $2K | Form 4 |
| 2026-08-27 | Ciongoli Gregory Austin · director | Open-market purchase | 53,407 | $9.36 | $500K | Form 4 |
| 2026-08-26 | Ciongoli Gregory Austin · director | Open-market purchase | 49,196 | $9.14 | $450K | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 176 reporting institutions held 42.6M shares ($349.7M).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | BlackRock, Inc. | 5,782,808 | $48.5M |
| 2 | Redmile Group, LLC | 4,368,804 | $36.6M |
| 3 | JPMORGAN CHASE & CO | 3,483,800 | $27.1M |
| 4 | STATE STREET CORP | 2,731,485 | $22.9M |
| 5 | MORGAN STANLEY | 2,066,157 | $17.3M |
| 6 | VANGUARD CAPITAL MANAGEMENT LLC | 2,007,146 | $16.8M |
| 7 | GOLDMAN SACHS GROUP INC | 1,839,463 | $15.4M |
| 8 | Integral Health Asset Management, LLC | 1,500,000 | $12.6M |
| 9 | Qube Research & Technologies Ltd | 1,310,493 | $11.0M |
| 10 | GEODE CAPITAL MANAGEMENT, LLC | 1,137,498 | $9.5M |
| 11 | AQR CAPITAL MANAGEMENT LLC | 1,051,712 | $8.8M |
| 12 | VANGUARD PORTFOLIO MANAGEMENT LLC | 1,018,901 | $8.5M |
| 13 | DIMENSIONAL FUND ADVISORS LP | 1,010,381 | $8.5M |
| 14 | Assenagon Asset Management S.A. | 980,611 | $8.2M |
| 15 | Nuveen, LLC | 582,016 | $4.9M |